BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734.

Mainstay Medical Holdings plc (the “Company”) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation™ system to treat intractable chronic low back pain.

Artugen Therapeutics’ Bharat Dixit Invited to Moderate Digital Panel at 6 th Microbiome Movement – Drug Development Summit on July 1 , 2021

Collaboration between leading AI-enabled oncology corporations helps provide the best arsenal available for advanced cancer patients

Dr Abbot’s appointment further strengthens Turnstone’s senior leadership team, adding depth and expertise in immune cell therapy

Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline

OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), is pleased to announce that it has retained the services of Ora, Inc., a world-class ophthalmology contract research organization (“CRO”), to guide the company’s upcoming product development and lead the regulatory strategy of OK-101 for the treatment of dry eye.

Neuros Medical, Inc., announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel High-Frequency Nerve Block system as an aid in the management of chronic intractable pain of the lower limb of adult amputees.

Baxter International Inc. announced today the introduction of three scholarship and grant programs to support Black students pursuing health and science degrees and ultimately help expand the pipeline of Black healthcare professionals.

StageZero Life Sciences announced that it will post its Annual and Special Meeting Update Presentation on the Company website on Wednesday, June 30, 2021 at 4:00 p.m. ET.